Estados Unidos - inglês - NLM (National Library of Medicine)

impax generics - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glyburide 1.25 mg - glyburide and metformin hydrochloride tablets, usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide and metformin hydrochloride tablets are contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73m2 ) (see warnings and precautions ). - known hypersensitivity to metformin hydrochloride or glyburide. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. - concomitant administration of bosentan. 

Estados Unidos - inglês - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glyburide 2.5 mg - glyburide and metformin hydrochloride tablets, usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide and metformin hydrochloride tablets are contraindicated in patients with: - renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥1.5 mg/dl [males], ≥1.4 mg/dl [females], or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see warnings  and precautions ). - known hypersensitivity to metformin hydrochloride or glyburide. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. - concomitant administration of bosentan. glyburide and metformin hydrochloride tablets should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, be

Estados Unidos - inglês - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glyburide 5 mg - glyburide and metformin hydrochloride tablets, usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide and metformin hydrochloride tablets are contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m 2 ) (see  warnings and  precautions ). - known hypersensitivity to metformin hydrochloride or glyburide. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. - concomitant administration of bosentan.

Estados Unidos - inglês - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glyburide 5 mg - glyburide and metformin hydrochloride tablets, usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide and metformin hydrochloride tablets are contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73m 2 ) (see warnings and precautions ). - known hypersensitivity to metformin hydrochloride or glyburide. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. - concomitant administration of bosentan. 

Estados Unidos - inglês - NLM (National Library of Medicine)

medsource pharmaceuticals - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glyburide 5 mg - glyburide and metformin hydrochloride tablets usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide and metformin hydrochloride tablets are contraindicated in patients with: - renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥ 1.5 mg/dl [males], ≥ 1.4 mg/dl [females], or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see warnings and precautions ). - known hypersensitivity to metformin hydrochloride or glyburide. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. - concomitant administration of bosentan. glyburide and metformin should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such prod

Estados Unidos - inglês - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc) - glyburide 5 mg - glyburide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide tablets are contraindicated in patients with: - known hypersensitivity or allergy to the drug. - diabetic ketoacidosis, with or without coma. this condition should be treated with insulin. - type i diabetes mellitus.

Estados Unidos - inglês - NLM (National Library of Medicine)

rebel distributors corp - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc) - glyburide 5 mg - glyburide tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide tablets are contraindicated in patients with: - known hypersensitivity or allergy to the drug. - diabetic ketoacidosis, with or without coma. this condition should be treated with insulin. - type i diabetes mellitus. special warning on increased risk of cardiovascular mortality the administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. this warning is based on the study conducted by the university group diabetes program (ugdp), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. the study involved 823 patients who were randomly assigned to one of four treatment groups. ugdp reported that patients

Estados Unidos - inglês - NLM (National Library of Medicine)

blenheim pharmacal, inc. - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc) - glyburide 2.5 mg - glyburide tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide tablets are contraindicated in patients: - with known hypersensitivity the drug or any of its excipients. - diabetic ketoacidosis, with or without coma. this condition should be treated with insulin. - type i diabetes mellitus. - concomitant administration of bosentan. warnings special warning on increased risk of cardiovascular mortality the administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. this warning is based on the study conducted by the university group diabetes program (ugdp), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. the study involved 823 patients who were randomly assigned

Estados Unidos - inglês - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc) - glyburide 2.5 mg - glyburide tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide tablets are contraindicated in patients: - with known hypersensitivity the drug or any of its excipients. - diabetic ketoacidosis, with or without coma. this condition should be treated with insulin. - type i diabetes mellitus. - concomitant administration of bosentan. warnings special warning on increased risk of cardiovascular mortality the administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. this warning is based on the study conducted by the university group diabetes program (ugdp), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. the study involved 823 patients who were randomly assigned

Estados Unidos - inglês - NLM (National Library of Medicine)

dispensing solutions, inc. - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc) - glyburide 2.5 mg - glyburide tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide tablets are contraindicated in patients with: - known hypersensitivity or allergy to the drug. - diabetic ketoacidosis, with or without coma. this condition should be treated with insulin. - type i diabetes mellitus. special warning on increased risk of cardiovascular mortality the administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. this warning is based on the study conducted by the university group diabetes program (ugdp), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. the study involved 823 patients who were randomly assigned to one of four treatment groups. ugdp reported that patients